Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARIA
  • CUSIP: 04033A10
  • Web: www.ariad.com
Average Prices:
  • 50 Day Moving Avg: $21.86
  • 200 Day Moving Avg: $14.14
  • 52 Week Range: $4.67 - $23.99
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -57.12
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -60.47%
  • Return on Assets: -17.16%
Debt:
  • Debt-to-Equity Ratio: -11.28%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.15%
Misc:
  • Average Volume: 9.91 million shs.
  • Beta: 2.16
 
Frequently Asked Questions for Ariad Pharmaceuticals (NASDAQ:ARIA)

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its quarterly earnings data on Thursday, July, 28th. The company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.70. The firm had revenue of $65.30 million for the quarter, compared to analyst estimates of $60.64 million. The company's revenue was up 133.0% compared to the same quarter last year. During the same period last year, the business earned ($0.28) EPS. View Ariad Pharmaceuticals' Earnings History.

Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 12-month target prices for Ariad Pharmaceuticals' shares. Their forecasts range from $7.00 to $24.00. On average, they anticipate Ariad Pharmaceuticals' share price to reach $16.54 in the next year. View Analyst Ratings for Ariad Pharmaceuticals.

Who are some of Ariad Pharmaceuticals' key competitors?

How do I buy Ariad Pharmaceuticals stock?

Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ariad Pharmaceuticals' stock price today?

One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.


MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  664
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $16.54 (31.05% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/11/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$24.00N/AView Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$16.00N/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2017Barclays PLCUpgradeUnderweight -> Equal Weight$9.00 -> $24.00N/AView Rating Details
1/10/2017Jefferies Group LLCDowngradeBuy -> Hold$11.00 -> $24.00N/AView Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageHold$9.50N/AView Rating Details
10/24/2016J P Morgan Chase & CoDowngradeNeutral -> Underweight$9.97 -> $7.00N/AView Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingHoldN/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$7.00 -> $5.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings History by Quarter for Ariad Pharmaceuticals (NASDAQ ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.19)($0.14)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.12)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314($0.30)($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.27)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
2017 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ariad Pharmaceuticals (NASDAQ:ARIA)
Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
Source:
DateHeadline
News IconEx-Ariad employee's husband charged in US with insider trading - Business Insider
www.businessinsider.com - July 22 at 3:56 PM
reuters.com logoEx-Ariad employee's husband charged with insider trading
www.reuters.com - July 22 at 3:34 AM
reuters.com logoEx-Ariad employee's husband charged with insider trading - Reuters - Reuters
www.reuters.com - July 21 at 3:30 AM
reuters.com logoEx-Ariad employee's husband charged in U.S. with insider trading - Reuters
www.reuters.com - July 20 at 5:26 PM
finance.yahoo.com logoWhat Sprycel Could Mean for Bristol-Myers Squibb
finance.yahoo.com - July 10 at 4:02 PM
seekingalpha.com logoMerrimack: A Special Situation With A Compelling Risk/Reward
seekingalpha.com - July 6 at 5:23 PM
bizjournals.com logo​SEC charges two former Ariad Pharmaceuticals executives with ... - Boston Business Journal
www.bizjournals.com - June 29 at 5:06 PM
marketwatch.com logoSEC charges three with insider trading in cancer drug company - MarketWatch
www.marketwatch.com - June 27 at 3:45 PM
finance.yahoo.com logo​SEC charges two former Ariad executives with insider trading
finance.yahoo.com - June 27 at 3:45 PM
seekingalpha.com logoMersana Therapeutics Kicks Off A Major IPO Week
seekingalpha.com - June 26 at 9:14 PM
nasdaq.com logoBellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ...
www.nasdaq.com - May 12 at 4:10 PM
streetinsider.com logoAlnylam Pharma (ALNY) Names Manmeet S. Soni as CFO - StreetInsider.com
www.streetinsider.com - May 9 at 9:09 AM
businesswire.com logoTakeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical Oncology
www.businesswire.com - May 8 at 10:49 AM
americanbankingnews.com logoFavorable News Coverage Extremely Likely to Affect Ariad Pharmaceuticals (ARIA) Stock Price
www.americanbankingnews.com - May 4 at 9:42 AM
nasdaq.com logoMonday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda
www.nasdaq.com - April 30 at 2:27 AM
nasdaq.com logoGeneral American Investors Co Inc Buys Ensco PLC, Johnson Controls International PLC, Liberty ...
www.nasdaq.com - April 29 at 4:14 PM
seekingalpha.com logoEvercore Partners' (EVR) CEO Ralph Schlosstein on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 3:53 PM
americanbankingnews.com logoPositive News Coverage Very Likely to Affect Ariad Pharmaceuticals (ARIA) Share Price
www.americanbankingnews.com - April 22 at 10:22 AM
americanbankingnews.com logoAriad Pharmaceuticals, Inc. (ARIA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 8:40 AM
americanbankingnews.com logoPositive Media Coverage Likely to Impact Ariad Pharmaceuticals (ARIA) Stock Price
www.americanbankingnews.com - April 17 at 12:07 PM
baystreet.ca logoAriad Pharmaceuticals (ARIA) Flat with Quarterly Loss Projected
www.baystreet.ca - April 12 at 11:48 AM
seekingalpha.com logoTocagen IPO Could Garner Significant Investor Attention
seekingalpha.com - April 11 at 8:05 AM
bloomberg.com logo7-Eleven to Buy Sunoco Shops in Record $3.3 Billion U.S. Bet
www.bloomberg.com - April 7 at 3:38 PM
finance.yahoo.com logoFormer Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale
finance.yahoo.com - April 7 at 8:05 AM
finance.yahoo.com logoThe Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors
finance.yahoo.com - March 31 at 3:45 PM
americanbankingnews.com logoAriad Pharmaceuticals, Inc. (ARIA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 31 at 10:29 AM
americanbankingnews.com logoAriad Pharmaceuticals, Inc. (ARIA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 3:19 PM
thestreet.com logoAfter Soaring to $150, Can Incyte Stir Up More Upside?
www.thestreet.com - March 15 at 3:49 PM
nasdaq.com logoTrump???s Immigration Plans an Overhang on Biotech ETFs?
www.nasdaq.com - March 2 at 3:51 PM
reuters.com logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters
www.reuters.com - February 18 at 3:34 PM
reuters.com logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals
www.reuters.com - February 17 at 6:32 PM
prnewswire.com logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
www.prnewswire.com - February 16 at 8:41 PM
prnewswire.com logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
www.prnewswire.com - February 16 at 8:41 PM
streetinsider.com logoTakeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA)
www.streetinsider.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM
finance.yahoo.com logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - Yahoo Finance
finance.yahoo.com - February 16 at 3:40 PM
finance.yahoo.com logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
au.finance.yahoo.com - February 16 at 3:40 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
us.rd.yahoo.com - February 8 at 8:53 PM
finance.yahoo.com logoARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
finance.yahoo.com - February 7 at 4:31 PM
investopedia.com logoAriad Submits Brigatinib Marketing Application (ARIA)
www.investopedia.com - February 7 at 1:44 AM
rttnews.com logoARIAD Pharma Reports Submission Of MAA For Brigatinib To EMA
www.rttnews.com - February 7 at 1:44 AM
us.rd.yahoo.com logo7:35 am Ariad Pharm submits a MMA for its ALK inhbiter, brigatinib, to the EMA
us.rd.yahoo.com - February 7 at 1:44 AM
us.rd.yahoo.com logoARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
us.rd.yahoo.com - February 7 at 1:44 AM

Social

Chart

Ariad Pharmaceuticals (ARIA) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff